Epigallocatechin‐3‐gallate activates the AMP‐activated protein kinase signaling pathway to reduce lipid accumulation in canine hepatocytes

Epigallocatechin‐3‐gallate (EGCG) plays a crucial role in hepatic lipid metabolism. However, the underlying regulatory mechanism of hepatic lipid metabolism by EGCG in canine is unclear. Primary canine hepatocytes were treated with EGCG (0.01, 0.1, or 1 μM) and BML‐275 (an AMP‐activated protein kinase [AMPK] inhibitor) to study the effects of EGCG on the gene and protein expressions associated with AMPK signaling pathway. Data showed that...